. Author manuscript; available in PMC: 2013 Dec 15.

Published in final edited form as: Bioorg Med Chem. 2012 Oct 12;20(24):7083–7094. doi: 10.1016/j.bmc.2012.10.001

Table 2.

In vitro cell growth inhibitory effects of compound 3d–e, 3k on drug resistant cell lines

Compd	IC₅₀ ^a (nM)		Resistance ratio^b
Compd	LoVo	LoVo^Doxo	Resistance ratio^b
3d	190 ± 70	152 ± 14	0.8
3e	31 ± 4.5	14.5 ± 1.2	0.5
3k	72 ± 16	150 ± 25	2.1
Doxorubicin^c	120 ± 30	13150 ± 210	109.6
	CEM	CEM^Vbl100	Resistance ratio^b
3d	10 ± 3.5	15 ± 4.6	1.5
3e	0.8 ± 0.1	1.2 ± 0.2	2.9
3k	61 ± 18	88 ± 12	1.4
Vinblastine	0.8 ± 0.1	205 ± 46	256.2
	A549	A549-T12	Resistance ratio^b
3d	138 ± 26	125 ± 23	0.9
3e	38.6 ± 7.3	21.5 ± 9.0	0.5
3k	119 ± 22	121 ± 36	1.0
Taxol^c	7.2 ± 0.1	75.2 ± 12.5	10.4

IC₅₀ = compound concentration required to inhibit tumor cell proliferation by 50%. Data are expressed as the mean ± SE from the dose–response curves of at least three independent experiments.

The values express the ratio between the IC₅₀’s determined in resistant and non-resistant cell lines.

Data from Ref. 8.